fda

August 30, 2017

First Gene Therapy Treatment Approved

The FDA announced approval of the first gene therapy for leukemia. From pharmaceutical giant Novartis, in collaboration with University of Pennsylvania’s Perelman School of Medicine, clinical trials, based on research funded by ACGT, resulted in 83% remission for pediatric patients with acute lymphocytic leukemia [ALL]. Read More

The Levis Family with Dr. Savio L.C. Woo, Chairman Emeritus ACGT Scientific Advisory Council

June 3, 2016

Back on Par

In 2012, Bob Levis, an Allentown, Pennsylvania resident, believed he had come to the end of his life. Diagnosed in 2002 with chronic lymphocytic leukemia, … Read More

The mission of ACGT is to seek out and support revolutionary scientific research into the causes, treatment and prevention of all types of cancer using cells and genes as medicine.

Cell and gene therapies are destroying tumors every day in the laboratory and in human trials, targeting only the cancer with few side effects to healthy tissue.  ACGT’s rigorous grant review process, under the guidance of a preeminent Scientific Advisory Council,  have resulted in some of the most successful breakthroughs in the history of cancer treatments and led to many patients in complete remission.

100% of our funding supports innovation and translational science that is proving again and again to offer better treatment options than the traditional therapies of chemotherapy, surgery and radiation. Every donation brings us closer to saving lives and changing the way we treat cancer forever.